Itaru Matsumura

19PUBLICATIONS
84CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Aug 14, 2026
ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

|Jul 24, 2026
Real-World Safety and Efficacy of Pola-R-CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients.

|Jun 18, 2026
Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

|Jun 11, 2026
Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

|Jan 04, 2026
Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.

Fumi Nakamura, Ken Ishiyama, Ritsuro Suzuki

|Oct 28, 2025
Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells.

Aki Fujii-Hanamoto, Hirokazu Tanaka, Ko Fujimoto

Pageof 4

Frequent Collaborators

7 joint publications

Hitoshi Kiyoi

6 joint publications

Takaaki Ono

6 joint publications

Naoto Takahashi

5 joint publications

Emiko Sakaida